Atropine

Stuart Therapeutics, Inc. Announces Upcoming Presentations at ARVO 2023 Annual Meeting

Retrieved on: 
Thursday, March 9, 2023
Conflict, University, Association for Research in Vision and Ophthalmology, Research, Vanderbilt University Medical Center, Therapy, Atropine, Meesmann corneal dystrophy, Telecanthus, Annual general meeting, University of Rochester, ARVO, Visual Science, Vanderbilt University, Neurotrophic keratitis, Medical imaging, Ophthalmology

STUART, Fla., March 9, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced that it is sponsoring two research poster presentations by researchers at Vanderbilt University and the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will take place from April 23-27, 2023, in New Orleans, Louisiana.

Key Points: 
  • STUART, Fla., March 9, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced that it is sponsoring two research poster presentations by researchers at Vanderbilt University and the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will take place from April 23-27, 2023, in New Orleans, Louisiana.
  • Dr. Wareham will present in vivo research results demonstrating corneal and trigeminal nerve repair capabilities of Collagen Mimetic Peptides (CMPs) under development by Stuart Therapeutics for anterior segment indications including dry eye disease, neurotrophic keratitis, and other corneal dystrophies.
  • This research shows for the first time that CMPs are capable of repairing and restoring the neural circuit between the corneal nerves and the lacrimal nerve and lacrimal gland.
  • The research was conducted at the Department of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute,Vanderbilt University Medical Center.

Luminopia, Inc. Announces Oversubscribed Seed Extension Financing Round

Retrieved on: 
Friday, November 11, 2022
Children, Clinical Trials, Health Technology, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Optical, Dai, Visual acuity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Academy, FDA, Ageing, Amblyopia, Eye, Food, Anisometropia, Astigmatism, VR, Parent, Atropine, De novo, Neuro, Technology, Severe cognitive impairment, Strabismus, Silicon, Partner, Patient, Cataract, Safety, Silicon Valley Bank, New Device, Far-sightedness, Biotechnology, Hospital, Entrepreneurship, American Academy of Ophthalmology, Therapy, Virtual reality, HMDS, Myopia, HMD, Physician, Industry, Compliance, Pharmaceutical industry, MD, Ophthalmology

Luminopia, Inc., a prescription digital therapeutics company pioneering a new class of treatments for neuro-visual disorders, today announced an oversubscribed $5.7M seed extension financing round.

Key Points: 
  • Luminopia, Inc., a prescription digital therapeutics company pioneering a new class of treatments for neuro-visual disorders, today announced an oversubscribed $5.7M seed extension financing round.
  • ShangBay Capital led the round, with participation from Sony Innovation Fund, The Vertical Group, and SSI Strategy, as well as support from existing investors.
  • With the closing of the round, William Dai, Founding Managing Partner of ShangBay Capital, will be joining Luminopias Board of Directors.
  • Upon launch, the therapeutic will be prescribed by eye care professionals and distributed through an online retail pharmacy.

Harrow Launches Atropine.com

Retrieved on: 
Thursday, November 10, 2022
Technology, FDA, Clinical Trials, Biotechnology, Internet, Pharmaceutical, Health, Optical, Retail, Online Retail, Forward-looking statement, Marketing, Health care, U.S. Securities and Exchange Commission, Prescription, FDA, Atropine, Research, Compound, Private Securities Litigation Reform Act, Family, Multimedia, SEC, Annual report, Pharmacy, Safety, Optometry, Patient, Physician, Ophthalmology, Security (finance), COVID-19, Pharmaceutical industry, Medicinal plants

Harrow (Nasdaq: HROW) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies that are accessible and affordable.

Key Points: 
  • Harrow (Nasdaq: HROW) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies that are accessible and affordable.
  • For more information about Harrow, including investor-related materials, please visit the corporate website, harrowinc.com , or Harrows LinkedIn page.
  • ImprimisRx is a wholly owned subsidiary of Harrow (Nasdaq: HROW).
  • Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Vyluma Completes Last Patient Visit for Primary Analysis of Pivotal Phase III CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Children

Retrieved on: 
Thursday, September 1, 2022
Cataract, Myopia, Safety, Life, Severe cognitive impairment, Trial of the century, Doctor of Philosophy, Glasses, Glaucoma, Hope, Phase, Approximation error, Science, MD, GLOBE, Atropine, Prevalence, Company, FDA, Population, Risk, Lens (anatomy), CHAMP, Eye, Cover My Eyes (Pain and Heaven), First Ever, Patient, Pharmaceutical industry

The CHAMP study has been designed, in collaboration with FDA, to evaluate whether NVK002 eye drops are safe and effective as a treatment for the progression of myopia in children.

Key Points: 
  • The CHAMP study has been designed, in collaboration with FDA, to evaluate whether NVK002 eye drops are safe and effective as a treatment for the progression of myopia in children.
  • With this milestone, Vyluma remains on track for primary analysis readout later this year and regulatory submission in 2023.
  • NVK002 is a proprietary, investigational, preservative-free eye drop administered nightly, which, if approved, would be the first-in-class pharmaceutical treatment for myopia progression in children.
  • Vylumas pipeline of therapies is led by NVK002, an investigational, preservative-free, low-dose atropine eye drop to treat the progression of myopia in children.

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

Retrieved on: 
Wednesday, August 3, 2022
World, Motherboard, Atropine, Ageing, State Council, Parent, Eye, Safety, Episode I, Sun, Ministry, Director, Company, Fudan University, S. D. Warren Co. v. Maine Board of Environmental Protection, Eye and ENT Hospital of Fudan University, Control, Research, World Health Organization, Technology, US Foods, Growth, List of education ministries, Education, Business, Adolescence, Food, SEHK, CEO, Board, Ophthalmology, Achievement, FDA, Benjamin, National Health Planning and Resources Development Act, Cover My Eyes (Pain and Heaven), Approximation error, Beijing Tongren Hospital, NDA, CIC, The Company, Hospital, Principal, Hong Kong Stock Exchange, Patient, Overalls, Pharmaceutical industry, Vaccine, Medical imaging, Myopia

The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.

Key Points: 
  • The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
  • These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
  • Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.

U.S. Department of Defense Awards $5.1 Million to Humanetics Corporation for Continued Development of Radiation Countermeasure

Retrieved on: 
Tuesday, June 21, 2022
Research, Other Health, General Health, Radiology, Pharmaceutical, Oncology, White House, Federal Government, Other Policy Issues, Clinical Trials, Science, FDA, Health, Public Policy, Government, Department, Radiation exposure, FDA, COVID-19, U.S. Department of Defense Strategy for Operating in Cyberspace, DOD, Naloxone, CEO, Humanetics, BIO, Cancer, Fort Detrick, Atropine, Research, Armed Forces Radiobiology Research Institute, Acquisition, Radiation, Patient, Military personnel, Risk, Pharmaceutical industry

Minneapolis-based Humanetics Corporation (Humanetics) has entered into a new $5.1 million cooperative research agreement with the U.S. Department of Defense (DOD) to continue advanced development of BIO 300, a medical countermeasure to protect military personnel and first responders from the harm caused by radiation exposure.

Key Points: 
  • Minneapolis-based Humanetics Corporation (Humanetics) has entered into a new $5.1 million cooperative research agreement with the U.S. Department of Defense (DOD) to continue advanced development of BIO 300, a medical countermeasure to protect military personnel and first responders from the harm caused by radiation exposure.
  • Auto injectors are commonly used by the military to deliver fast-acting drugs such as atropine and naloxone.
  • The drug was licensed to Humanetics Corporation, which is leading its advanced development toward FDA approval.
  • We are enthused and encouraged by the DODs continued investment in the development of BIO 300 as a medical countermeasure, said Zenk.

Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)

Retrieved on: 
Monday, March 14, 2022
Hypertension, AmerisourceBergen, U.S. Securities and Exchange Commission, Therapy, Atropine, Degenerative disease, Private Securities Litigation Reform Act, Injection, Bradycardia, Bromide, Nervous, Oxytocin, Stroke, Growth, National, Intubation, New Drug Application, Carglumic acid, Safety, McKesson Corporation, Restless, Theophylline, FDA, Anesthesia, Tachyphylaxis, Temperature, Dizziness, Cardinal Health, MAOI, GLOBE, Nausea, Patient, Quinidine, Arrhythmia, Digitalis, Clonidine, XGen Studios, CEO, Ephedrine, Insomnia, Reserpine, Vomiting, Security (finance), Xanthine oxidase inhibitor, Ownership, Hypotension, Sulfite, Nasdaq, Incidence, Mephentermine, Guanethidine, Palpitations, Hospital, Tachycardia, Plasma protein binding, IQVIA, Goal, Pharmaceutical industry

DEER PARK, Ill., March 14, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres (ephedrine hydrochloride) injection.

Key Points: 
  • DEER PARK, Ill., March 14, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres (ephedrine hydrochloride) injection.
  • Rezipres (4.7 mg/mL) is a ready-to-use1 formulation of injectable ephedrine hydrochloride that is approved for the treatment of clinically important hypotension occurring in the setting of anesthesia.
  • We look forward to partnering with XGen DJB given their extensive track record of successfully commercializing injectable products in the hospital setting, said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
  • We are delighted to be teaming up with Eton as the commercial partner in introducing their ready-to-use Rezipres product, which is the first FDA-approved hydrochloride-based ephedrine injectable formulation, added Edmund Vanderbeck, President of XGen Pharmaceuticals DJB.

Amneal Expands Injectables Portfolio with 4 New Products

Retrieved on: 
Thursday, February 17, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NYSE, Patient, Food, Risk, Carboprost, Company, Federation, CGT, Weather, Injection, Forward-looking statement, Medication, U.S. Securities and Exchange Commission, Security (finance), Baclofen, Annual report, Degenerative disease, SVP, Regulation of tobacco by the U.S. Food and Drug Administration, Tris, Abbreviated New Drug Application, USP, FDA, Saol, Generic, ANDA, Central nervous system, LVP, Private Securities Litigation Reform Act, Growth, Dexamethasone, Research, Investment, Amneal Pharmaceuticals, COVID-19, Azacitidine, Atropine, Peptide, Pharmaceutical industry, Fine chemical, Generic drug, Risk management

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the approval of four generic injectables products.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the approval of four generic injectables products.
  • An important element of Amneals long-term growth strategy is expanding our injectables business, and todays announcement of four new approvals is another key step.
  • The Company has a diverse portfolio of approximately 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars.
  • In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs.

Luminopia Announces FDA Approval of Digital Therapeutic that Uses TV Shows to Improve Vision in Children with Lazy Eye

Retrieved on: 
Wednesday, October 20, 2021
Software, Research, Pharmaceutical, Optical, Consumer, Technology, Clinical Trials, Science, Children, Audio, Video, FDA, Other Technology, Health, Safety, Virtual reality, MD, Compliance, HMD, Technology, Amblyopia, Strabismus, Myopia, American Academy, Ageing, Anisometropia, Patient, FDA, Astigmatism, Atropine, Food, Cleveland, VR, Cataract, Picower Institute for Learning and Memory, Eye, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Visual acuity, Brain, Hospital, Randomized controlled trial, Cleveland Clinic, HMDS, Learning, Sesame Workshop, Severe cognitive impairment, MIT, LogMAR chart, Therapy, Doctor of Philosophy, Parent, De novo, Pharmacy, Far-sightedness, Memory, Physician, Pharmaceutical industry, Telescopic sight, Luminopia One, Amblyopia4, Luminopia, LUMINOPIA ONE, AMBLYOPIA4, LUMINOPIA

Luminopia One allows patients to watch therapeutically modified TV shows and movies to improve their vision within a virtual reality (VR) headset.

Key Points: 
  • Luminopia One allows patients to watch therapeutically modified TV shows and movies to improve their vision within a virtual reality (VR) headset.
  • The FDA approval of a new digital therapy with robust clinical evidence for children affected by amblyopia is a major development.
  • The idea of prescribing TV shows and movies to treat amblyopia in children instead of eye patches or eye drops is an exciting prospect.
  • Luminopia One is the first FDA-approved digital therapeutic for a neuro-visual disorder in children, indicated to improve vision in children with amblyopia.

Luminopia One, a Digital Therapeutic for Amblyopia, Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial

Retrieved on: 
Tuesday, September 14, 2021
Children, Technology, Health, General Health, Optical, Research, Software, Consumer, Science, Clinical Trials, Parenting, LogMAR chart, Patient satisfaction, Amblyopia, Food, American Academy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neuro, FDA, Sesame Workshop, Learning, Massachusetts Institute of Technology, Clinical study design, Memory, De novo, Patient, Picower Institute for Learning and Memory, Software, Net, Algorithm, Far-sightedness, VR, MIT, Severe cognitive impairment, Safety, Cleveland, Strabismus, Therapy, NPS, Ageing, Myopia, Hospital, MSCE, Cleveland Clinic, Cataract, Review, Brain, Astigmatism, Randomized controlled trial, American Academy of Ophthalmology, Eye, Parent, Virtual reality, Atropine, Visual cortex, Pharmaceutical industry, Telescopic sight, Medical device, Luminopia One, Amblyopia5, Luminopia, LUMINOPIA ONE, AMBLYOPIA5, LUMINOPIA

The published study was a Phase 3 multicenter, randomized controlled clinical trial designed to evaluate the safety and efficacy of Luminopia One to treat amblyopia in children aged 4-7.

Key Points: 
  • The published study was a Phase 3 multicenter, randomized controlled clinical trial designed to evaluate the safety and efficacy of Luminopia One to treat amblyopia in children aged 4-7.
  • A link to the publication, Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia, can be found here: https://www.aaojournal.org/article/S0161-6420(21)00682-5/fulltext .
  • Luminopia One has been validated in multiple clinical trials, including a Phase 3 pivotal trial that demonstrated its safety and efficacy in children aged 4-7 for the treatment of amblyopia.
  • Luminopia is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients.